Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience ; volume:21 ; number:1 ; day:7 ; month:10 ; year:2023 ; pages:1-10 ; date:12.2023
World journal of surgical oncology ; 21, Heft 1 (7.10.2023), 1-10, 12.2023
- Urheber
-
Zaher, Haidi Abd El
Fathy, Hamada
Abozeid, Mohamed
Faisal, Mohammed
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12957-023-03199-z
- URN
-
urn:nbn:de:101:1-2024020808541419046131
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zaher, Haidi Abd El
- Fathy, Hamada
- Abozeid, Mohamed
- Faisal, Mohammed
- SpringerLink (Online service)
Ähnliche Objekte (12)
Nutritional Status Indicators Predict Tolerability to Adjuvant Chemotherapy in Patients with Stage II/III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy
Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
Neoadjuvant PD-(L)1 blockade with or without chemotherapy versus chemotherapy alone in mismatch repair-deficient, potentially resectable stage III-IVA gastric cancer patients: a single-center retrospective study
Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II–III triple negative breast cancer: a retrospective analysis
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience
Preoperative (neoadjuvant) chemotherapy : with 49 tables
Nutritional Status Indicators Predict Tolerability to Adjuvant Chemotherapy in Patients with Stage II/III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy
Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
Neoadjuvant PD-(L)1 blockade with or without chemotherapy versus chemotherapy alone in mismatch repair-deficient, potentially resectable stage III-IVA gastric cancer patients: a single-center retrospective study
Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II–III triple negative breast cancer: a retrospective analysis
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience
Preoperative (neoadjuvant) chemotherapy : with 49 tables
Nutritional Status Indicators Predict Tolerability to Adjuvant Chemotherapy in Patients with Stage II/III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy
Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
Neoadjuvant PD-(L)1 blockade with or without chemotherapy versus chemotherapy alone in mismatch repair-deficient, potentially resectable stage III-IVA gastric cancer patients: a single-center retrospective study
Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II–III triple negative breast cancer: a retrospective analysis
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience